Inflammation News and Research

RSS

Discovery of marker for severity in adult brain cancer

Researchers at UT Southwestern Medical Center have identified a new biological indicator that may help identify which brain-cancer patients have the most aggressive forms of the disease.

1 Apr 2009

The immune system's role in hepatitis C recurrence after liver transplantation

A new study pinpoints certain aspects of the immune system that may play a role in the recurrence and progression of hepatitis C virus (HCV) after liver transplantation.

1 Apr 2009

Omega-3 fatty acid found in fish oils kills cancer cells

Docosahexanoic acid (DHA), an omega-3 fatty acid found in fish oils, has been shown to reduce the size of tumours and enhance the positive effects of the chemotherapy drug cisplatin, while limiting its harmful side effects.

1 Apr 2009

Sorafenib may help patients suffering from advanced portal hypertension

In a new study, a therapeutic agent called sorafenib dramatically improved the condition of rats with portal hypertension.

1 Apr 2009

West Nile virus studies show how star-shaped brain cells cope with infection

A new study published as the cover article for the April 2009 issue of The FASEB Journal promises to give physicians new ways to reduce deadly responses to viral infections of the brain and spinal cord.

1 Apr 2009

New insights into how brain responds to viral infection

Scientists at Columbia University Mailman School of Public Health have discovered that astrocytes, supportive cells in the brain that are not derived from an immune cell lineage, respond to a molecule that mimics a viral infection using cellular machinery similar to that used by classical immune cells in the blood.

1 Apr 2009

By shutting down inflammation, agent reverses damage from spinal cord injury in preclinical studies

Researchers at Georgetown University Medical Center (GUMC) have been able to speed recovery and substantially reduce damage resulting from spinal cord injury in preclinical studies.

1 Apr 2009

Bad mix of bacterial remnants and NOD2 gene lead to arthritis

Here's another reason to hate leftovers. A research study appearing in the April 2009 issue of the Journal of Leukocyte Biology sheds light on one cause of arthritis: bacteria.

1 Apr 2009

Ultrasound saves money, improves rheumatologic care

A few years back, 76-year-old Joseph Buggie woke up to pain so throbbing, he couldn't muster the strength to roll over, let alone crawl out of bed.

31 Mar 2009

SARcode announces results of phase 1 trial of SAR 1118 ophthalmic solution in healthy adult subjects

SARcode Corporation announced today the results of its Phase 1 randomized, double-masked, placebo-controlled trial of the safety, tolerability, and pharmacokinetics of single- and multiple-escalating doses of SAR 1118 Ophthalmic Solution in healthy volunteers.

30 Mar 2009

Multiple sclerosis associated with lower cancer risk overall

A new study shows that people with multiple sclerosis may be at a lower risk for cancer overall, but at a higher risk of developing certain types of cancer, such as brain tumors and bladder cancer.

30 Mar 2009

FDA approves Afinitor oral tablets (everolimus) for advanced form of kidney cancer

The U.S. Food and Drug Administration today approved Afinitor oral tablets (everolimus) for the treatment of patients with advanced kidney cancer whose disease has progressed after treatment with other cancer therapies.

30 Mar 2009

Gene scan shows body's sleep cycle influences numerous physical functions

The pineal gland - integral to setting the body's sleep and wake cycles - may be involved in a broad range of bodily functions, according to a study by researchers at the National Institutes of Health and other institutions.

30 Mar 2009

Researchers find direct link between oxidative stress and inflammatory signals in the blood

The finding could lead to improved strategies for preventing several diseases by including antioxidants in the diet and for reducing the impact of inflammation in critically ill patients by adding cysteine to intravenous or tube feeding.

30 Mar 2009

NTRILIPIX (fenofibric acid) in combo with Rosuvastatin calcium shows improvement on key lipids for cholesterol management

Data from a new study showed that Abbott's TRILIPIX (fenofibric acid) delayed-release capsules in combination with rosuvastatin calcium met all of the study's primary endpoints.

29 Mar 2009

Enzyme and vitamin define the yin and yang of asthma

The allergen breathed in by a person with asthma triggers a proteinase or enzyme called MMP7 that activates a cascade of events to prompt an allergic reaction, said a consortium of researchers led by Baylor College of Medicine in Houston in a report that appears online in the journal Nature Immunology.

29 Mar 2009

CRESTOR found to reduced CV risk in patients achieving low LDL-C and hsCRP targets in new Jupiter analysis

Results from a new sub-analysis of the JUPITER study show that patients who attained a dual treatment target of LDL-C <70mg/dL and high-sensitivity C-reactive protein (hsCRP) <2mg/L with CRESTOR (rosuvastatin) 20mg achieved a greater reduction in cardiovascular events compared to placebo than those who did not (65% vs 36%, p=0.033) among men and women with low to normal cholesterol levels and elevated hsCRP.

29 Mar 2009

CRESTOR (rosuvastatin) shown to significantly reduce risk of venous thromboembolism

A new analysis from the JUPITER study shows that CRESTOR (rosuvastatin) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p=0.007) compared to placebo among men and women with low to normal cholesterol levels and elevated high-sensitivity C-reactive protein (hsCRP).

29 Mar 2009

RegeneRx reports phase II venous stasis trial results

Regenerx Biopharmaceuticals Inc. has announced the results of its Phase II clinical trial evaluating the safety and wound-healing efficacy of RGN-137 for the treatment of patients with venous stasis ulcers.

29 Mar 2009

Positive phase 3 uveitis trial results for voclosporin

Isotechnika Inc. has announced that their partner, Lux Biosciences, Inc., reported the results from the three Phase 3 LUMINATE trials investigating voclosporin oral capsule (LUVENIQ or LX211) for the treatment of uveitis.

29 Mar 2009